Financial and Clinical Implications of Intramuscular Versus Subcutaneous Interferon Beta-1a in Portugal, Based on the Findings From the Cochrane Collaboration Review of First-Line Treatments for Relapsing-Remitting Multiple Sclerosis

Value in Health - United Kingdom

doi 10.1016/j.jval.2014.08.887